FDA Orange Book
Is there a generic for Zavzpret?
Zavzpret contains zavegepant. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zavzpret (zavegepant). The Orange Book shows its last listed patent expires June 26, 2034 and its last listed exclusivity ends March 9, 2028.
Run it in Rivvi
Map Zavzpret and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Zavzpret products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| spray, metered, nasal | EQ 10MG BASE/SPRAY | Marketed (Rx) | None | 0 | None |
NDA 216386, held by PFIZER INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Zavzpret patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 8481546 | June 26, 2034 | Drug substance, Drug product | U-3555 | 216386 |
Zavzpret exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NCE | New chemical entity | March 9, 2028 | 216386 |
Zavzpret NDC codes
Questions
Is there a generic for Zavzpret?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zavzpret (zavegepant). The Orange Book shows its last listed patent expires June 26, 2034 and its last listed exclusivity ends March 9, 2028.
What is the generic name for Zavzpret?
The active ingredient in Zavzpret is zavegepant, per the FDA Orange Book.
When does the Zavzpret patent expire?
The last patent listed for Zavzpret in the Orange Book expires June 26, 2034. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.